CD8A and cancer: Conventional cytotoxic CD8+ T lymphocytes (CTLs) recognize peptide antigens presented by MHC class I, and CD4+ T cells engage with peptide-MHC class II complexes (3), driving crucial anticancer immune responses and framing cancer immunotherapies (4, 5).